GRP-78 secreted by tumor cells blocks the antiangiogenic activity of bortezomib

Blood - Tập 114 - Trang 3960-3967 - 2009
Johann Kern1, Gerold Untergasser1, Christoph Zenzmaier2, Bettina Sarg3, Guenther Gastl1, Eberhard Gunsilius1, Michael Steurer4
1Tumor Biology & Angiogenesis Laboratory, Department of Internal Medicine V, Innsbruck Medical University, Innsbruck
2Institute for Biomedical Aging Research, Innsbruck
3Division of Clinical Chemistry, Biocenter, Innsbruck Medical University, Innsbruck
4Laboratory for Molecular Genetics, Department of Internal Medicine V, Innsbruck Medical University, Innsbruck, Austria

Tóm tắt

Abstract

Antiangiogenic effects of the proteasome inhibitor bortezomib were analyzed on tumor xenografts in vivo. Bortezomib strongly inhibited angiogenesis and vascularization in the chicken chorioallantoic membrane. Bortezomib's inhibitory effects on chorioallantoic membrane vascularization were abrogated in the presence of distinct tumor xenografts, thanks to a soluble factor secreted by tumor cells. Through size-exclusion and ion-exchange chromatography as well as mass spectroscopy, we identified GRP-78, a chaperone protein of the unfolded protein response, as being responsible for bortezomib resistance. Indeed, a variety of bortezomib-resistant solid tumor cell lines (PC-3, HRT-18), but not myeloma cell lines (U266, OPM-2), were able to secrete high amounts of GRP-78. Recombinant GRP-78 conferred bortezomib resistance to endothelial cells and OPM-2 myeloma cells. Knockdown of GRP78 gene expression in tumor cells and immunodepletion of GRP-78 protein from tumor cell supernatants restored bortezomib sensitivity. GRP-78 did not bind or complex bortezomib but induced prosurvival signals by phosphorylation of extracellular signal–related kinase and inhibited p53-mediated expression of proapoptotic Bok and Noxa proteins in endothelial cells. From our data, we conclude that distinct solid tumor cells are able to secrete GRP-78 into the tumor microenvironment, thus demonstrating a hitherto unknown mechanism of resistance to bortezomib.


Tài liệu tham khảo

Teicher, 1999, The proteasome inhibitor PS-341 in cancer therapy., Clin Cancer Res, 5, 2638 Sunwoo, 2001, Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma., Clin Cancer Res, 7, 1419 Boccadoro, 2005, Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy., Cancer Cell Int, 5, 18, 10.1186/1475-2867-5-18 Richardson, 2003, Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers., Cancer Control, 10, 361, 10.1177/107327480301000502 Adams, 2001, Proteasome inhibition in cancer: development of PS-341., Semin Oncol, 28, 613, 10.1016/S0093-7754(01)90034-X Adams, 2004, The development of proteasome inhibitors as anticancer drugs., Cancer Cell, 5, 417, 10.1016/S1535-6108(04)00120-5 Williams, 2003, Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts., Mol Cancer Ther, 2, 835 Roccaro, 2006, Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells., Cancer Res, 66, 184, 10.1158/0008-5472.CAN-05-1195 Papageorgiou, 2006, Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells., Mol Cancer Ther, 5 (12), 3032, 10.1158/1535-7163.MCT-05-0474 Brignole, 2006, Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis., J Natl Cancer Inst, 98, 1142, 10.1093/jnci/djj309 Oikawa, 1998, The proteasome is involved in angiogenesis., Biochem Biophys Res Commun, 246, 243, 10.1006/bbrc.1998.8604 Steurer, 2003, Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha., Br J Haematol, 121, 101, 10.1046/j.1365-2141.2003.04252.x Groll, 2006, Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome., Structure, 14, 451, 10.1016/j.str.2005.11.019 Bianchi, 2009, The proteasome load vs capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition., Blood, 113, 3040, 10.1182/blood-2008-08-172734 Parker, 2001, Identification of TFII-I as the endoplasmic reticulum stress response element binding factor ERSF: its autoregulation by stress and interaction with ATF6., Mol Cell Biol, 21, 3220, 10.1128/MCB.21.9.3220-3233.2001 Jaffe, 1973, Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria., J Clin Invest, 52, 2745, 10.1172/JCI107470 Zenzmaier, 2008, Dysregulation of Dkk-3 expression in benign and malignant prostatic tissue., Prostate, 68, 540, 10.1002/pros.20711 Kern, 2008, Alternative splicing of vasohibin-1 generates an inhibitor of endothelial cell proliferation, migration, and capillary tube formation., Arterioscler Thromb Vasc Biol, 28, 478, 10.1161/ATVBAHA.107.160432 Untergasser, 2001, A low-molecular-weight fraction of human seminal plasma activates adenylyl cyclase and induces caspase 3-independent apoptosis in prostatic epithelial cells by decreasing mitochondrial potential and Bcl-2/Bax ratio., FASEB J, 15, 673, 10.1096/fj.00-0270com Jiang, 2003, Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia., Amino Acids, 25, 49, 10.1007/s00726-003-0356-6 Zenzmaier, 2005, Proteomic profiling of human stem cells derived from umbilical cord blood., Biochem Biophys Res Commun, 328, 968, 10.1016/j.bbrc.2005.01.044 Oerlemans, 2008, Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein., Blood, 112, 2489, 10.1182/blood-2007-08-104950 Liu, 2007, Cytoprotective effects of proteasome beta5 subunit overexpression in lens epithelial cells., Mol Vis, 13, 31 Fuchs, 2008, Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells., J Cell Biochem, 103, 270, 10.1002/jcb.21405 Chauhan, 2003, Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells., Cancer Res, 63, 6174 Sun, 2006, Localization of GRP-78 to mitochondria under the unfolded protein response., Biochem J, 396, 31, 10.1042/BJ20051916 Virrey, 2008, Stress chaperone GRP-78/BiP confers chemoresistance to tumor-associated endothelial cells., Mol Cancer Res, 6, 1268, 10.1158/1541-7786.MCR-08-0060 Shani, 2008, GRP-78 and Cripto form a complex at the cell surface and collaborate to inhibit transforming growth factor beta signaling and enhance cell growth., Mol Cell Biol, 28 (2), 666, 10.1128/MCB.01716-07 Lee, 2007, GRP-78 induction in cancer: therapeutic and prognostic implications., Cancer Res, 67, 3496, 10.1158/0008-5472.CAN-07-0325 Strizzi, 2005, Cripto-1: a multifunctional modulator during embryogenesis and oncogenesis., Oncogene, 24, 5731, 10.1038/sj.onc.1208918
Thông tin
Thông tin xuất bản

Blood

Tập 114

3960-3967

Thông tin tác giả